ArticleAnalytical and bioanalytical chemistry2021
Quantitative mass spectrometry imaging of drugs and metabolites: a multiplatform comparison.
Article in Analytical and bioanalytical chemistry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- The evolution of DESI-MSI: A comprehensive look at preprocessing and quantification strategies for metabolomics.Journal of food and drug analysis · 2026Review
- Past, present and future of drug conjugates for cancer therapy.Nature cancer · 2025Review
- Quantitative ambient mass spectrometry imaging in plants: A perspective on challenges and future applications.Current opinion in plant biology · 2025Review
- Spatial Distribution of Brain PET Tracers by MALDI Imaging.Journal of the American Society for Mass Spectrometry · 2025Article
- Off-target autophagy disruption associated with a novel liver toxicity in dogs for a highly basic heterobifunctional protein degrader.Frontiers in pharmacology · 2025Article
- Mass Spectrometry Imaging for Spatial Toxicology Research.Journal of mass spectrometry : JMS · 2024Review
- Novel mimetic tissue standards for precise quantitative mass spectrometry imaging of drug and neurotransmitter concentrations in rat brain tissues.Analytical and bioanalytical chemistry · 2024Article
- An Analytical Evaluation of Tools for Lipid Isomer Differentiation in Imaging Mass Spectrometry.International journal of mass spectrometry · 2024Article
- Spatial neurolipidomics-MALDI mass spectrometry imaging of lipids in brain pathologies.Journal of mass spectrometry : JMS · 2024Review
- Quantitative mass spectrometry imaging: therapeutics & biomolecules.Chemical communications (Cambridge, England) · 2024Review
- Review
- Toward Omics-Scale Quantitative Mass Spectrometry Imaging of Lipids in Brain Tissue Using a Multiclass Internal Standard Mixture.Analytical chemistry · 2023Article
- Advances in Imaging Mass Spectrometry for Biomedical and Clinical Research.Trends in analytical chemistry : TRAC · 2023Article
- Metabolomics and lipidomics strategies in modern drug discovery and development.Drug discovery today · 2023Review
- Application of infrared matrix-assisted laser desorption electrospray ionization mass spectrometry for morphine imaging in brain tissue.Analytical and bioanalytical chemistry · 2023Article
- Promise of spatially resolved omics for tumor research.Journal of pharmaceutical analysis · 2023Review
- Chemical QuantArray: A Quantitative Tool for Mass Spectrometry Imaging.Analytical chemistry · 2023Article
- Targeted Desorption Electrospray Ionization Mass Spectrometry Imaging for Drug Distribution, Toxicity, and Tissue Classification Studies.Metabolites · 2023Article
- An Alternative Method for Quantitative Mass Spectrometry Imaging (Mass spectrometry (Tokyo, Japan) · 2023Article
- Perspective: Mass Spectrometry Imaging - The Next 5 Years.Methods in molecular biology (Clifton, N.J.) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Mass spectrometry imaging (MSI) provides insight into the molecular distribution of a broad range of compounds and, therefore, is frequently applied in the pharmaceutical industry. Pharmacokinetic and toxicological studies deploy MSI to localize potential drugs and their metabolites in biological tissues but currently require other analytical tools to quantify these pharmaceutical compounds in the same tissues. Quantitative mass spectrometry imaging (Q-MSI) is a field with challenges due to the high biological variability in samples combined with the limited sample cleanup and separation strategies available prior to MSI. In consequence, more selectivity in MSI instruments is required. This can be provided by multiple reaction monitoring (MRM) which uses specific precursor ion-product ion transitions. This targeted approach is in particular suitable for pharmaceutical compounds because their molecular identity is known prior to analysis. In this work, we compared different analytical platforms to assess the performance of MRM detection compared to other MS instruments/MS modes used in a Q-MSI workflow for two drug candidates (A and B). Limit of detection (LOD), linearity, and precision and accuracy of high and low quality control (QC) samples were compared between MS instruments/modes. MRM mode on a triple quadrupole mass spectrometer (QqQ) provided the best overall performance with the following results for compounds A and B: LOD 35.5 and 2.5 μg/g tissue, R
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.